In 2025, Celltrion Pharm completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Celltrion Pharm has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 5,061.97a | 5,159a | 5,301a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 9,655.27a | 10,332a | 10,405a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | N/A | 15.8428a | 17.4227a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Celltrion Pharm amounted to 14,717.24 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Celltrion Pharm decreased by 4.99%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Celltrion Pharm were 5,061.97 metric tons of CO₂ equivalent (tCO₂e).a
Since 2023, Celltrion Pharm's Scope 1 emissions have decreased by 4.51%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2024), Celltrion Pharm's Scope 1 emissions decreased by 1.88%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Celltrion Pharm reported Scope 2 greenhouse gas (GHG) emissions of 9,655.27 tCO₂e without specifying the calculation method.a
Since 2023, Celltrion Pharm's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Celltrion Pharm's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2024), Celltrion Pharm's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Celltrion Pharm's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Celltrion Pharm reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Celltrion Pharm reported Scope 1 greenhouse gas (GHG) emissions of 5,159 tCO₂e and total revenues of USD 326 millions. This translates into an emissions intensity of 15.84 tCO₂e per millions USD.a
In 2024, Celltrion Pharm reported a Scope 1 emissions intensity of 15.84 tCO₂e per millions USD. Compared to the peer group median of 23.01, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Celltrion Pharm ranked 9 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Celltrion Pharm is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a